ReviewFrontiers in microbiology2022
Feasibility of Hepatitis C Elimination in China: From Epidemiology, Natural History, and Intervention Perspectives.
Review in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Trends and forecasting of reported hepatitis B and hepatitis C incidence in Hainan Province, China, 2005-2020.Frontiers in epidemiology · 2026Article
- Epidemiological trends of hepatitis C incidence and death in Mainland China between 2004 and 2018 and its predictions to 2030.BMC infectious diseases · 2025Article
- Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study.Clinical and molecular hepatology · 2025Article
- The Natural History of Hepatitis C Virus Infection and Disease in the Era of Curative Therapy with Direct-Acting Antivirals.Viruses · 2025Review
- Influencing factors of HCV testing willingness among men who have sex with men in China: A structural equation modeling analysis.PloS one · 2025Article
- Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study.PharmacoEconomics · 2024Article
- HCV RNA positivity among hepatitis C patients in Chongqing, China from 2004 to 2021: a cross-sectional study.BMC infectious diseases · 2024Article
- Universal screening for HCV infection in China: An effectiveness and cost-effectiveness analysis.JHEP reports : innovation in hepatology · 2024Article
- Is it time for China to prioritize pan-genotypic regimens for treating patients with hepatitis C?Cost effectiveness and resource allocation : C/E · 2024Article
- Multi-disciplinary cooperation for the micro-elimination of hepatitis C in China: a hospital-based experience.BMC gastroenterology · 2023Article
- Performance Comparison of Machine Learning Approaches on Hepatitis C Prediction Employing Data Mining Techniques.Bioengineering (Basel, Switzerland) · 2023Article
- Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment.BMC gastroenterology · 2023Article
- Burden of Hepatocellular Carcinoma and Its Underlying Etiologies in China, 1990-2021: Findings From the Global Burden of Disease Study 2021.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C imposes a heavy burden on many countries, including China, where the number of reported cases and the incidence of hepatitis C virus (HCV) increased yearly from 2005 to 2012, with a stable trend after 2012. The geographical distribution of HCV infections varies widely in China, with the northwest and southwest regions and the Henan Province showing a high disease burden. Elderly, men, sexually active people, drug users, migrants, blood transfusion recipients, and renal dialysis patients have become the target populations for hepatitis C prevention and control. It is important to improve the diagnosis rate in high-risk groups and asymptomatic people. Identifying secondary HCV infections, especially in HCV patients co-infected with the human immunodeficiency virus (HIV) is a priority of hepatitis C prevention and control. Enhancing universal access to direct antiviral agents (DAAs) treatment regimens is an effective way to improve the cure rate of HCV infection. For China to contribute to the WHO 2030 global HCV elimination plan, strategic surveillance, management, and treatment program for HCV are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.